These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 36252018)
21. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells. Lombardo Y; Faronato M; Filipovic A; Vircillo V; Magnani L; Coombes RC Breast Cancer Res; 2014 Jun; 16(3):R62. PubMed ID: 24919951 [TBL] [Abstract][Full Text] [Related]
22. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice. Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007 [TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity. Zhang X; Wang ZY Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601 [TBL] [Abstract][Full Text] [Related]
24. Curcumol inhibits breast cancer growth Wei ZL; Juan W; Tong D; Juan LX; Sa LY; Jie HFM; Xiao G; Xiang LG; Jie HM; Xu C Food Funct; 2023 Jan; 14(2):874-885. PubMed ID: 36537297 [No Abstract] [Full Text] [Related]
25. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells. Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334 [TBL] [Abstract][Full Text] [Related]
26. MCAM/CD146 promotes tamoxifen resistance in breast cancer cells through induction of epithelial-mesenchymal transition, decreased ERα expression and AKT activation. Liang YK; Zeng D; Xiao YS; Wu Y; Ouyang YX; Chen M; Li YC; Lin HY; Wei XL; Zhang YQ; Kruyt FA; Zhang GJ Cancer Lett; 2017 Feb; 386():65-76. PubMed ID: 27838413 [TBL] [Abstract][Full Text] [Related]
27. Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer. Ito T; Kamijo S; Izumi H; Kohno K; Amano J; Ito K Breast Cancer Res Treat; 2012 May; 133(1):145-59. PubMed ID: 21863258 [TBL] [Abstract][Full Text] [Related]
28. Structural insights into tumor-specific chaperoning activity of gamma synuclein in protecting estrogen receptor alpha 36 and its role in tamoxifen resistance in breast cancer. Panneerselvam M; Muthu K; Ramadas K Mol Biosyst; 2015 Nov; 11(11):2998-3010. PubMed ID: 26299756 [TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Lindberg K; Helguero LA; Omoto Y; Gustafsson JÅ; Haldosén LA Breast Cancer Res; 2011 Apr; 13(2):R43. PubMed ID: 21492444 [TBL] [Abstract][Full Text] [Related]
30. Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover. Adomas AB; Grimm SA; Malone C; Takaku M; Sims JK; Wade PA BMC Cancer; 2014 Apr; 14():278. PubMed ID: 24758297 [TBL] [Abstract][Full Text] [Related]
31. USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor α. Cao J; Wu D; Wu G; Wang Y; Ren T; Wang Y; Lv Y; Sun W; Wang J; Qian C; He L; Yang K; Li H; Gu H Cell Death Dis; 2021 Jun; 12(6):619. PubMed ID: 34131114 [TBL] [Abstract][Full Text] [Related]
32. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells. Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335 [TBL] [Abstract][Full Text] [Related]
33. During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein. Salazar MD; Ratnam M; Patki M; Kisovic I; Trumbly R; Iman M; Ratnam M Breast Cancer Res; 2011 Feb; 13(1):R18. PubMed ID: 21299862 [TBL] [Abstract][Full Text] [Related]
34. GATA3 mRNA expression, but not mutation, associates with longer progression-free survival in ER-positive breast cancer patients treated with first-line tamoxifen for recurrent disease. Liu J; Prager-van der Smissen WJ; Look MP; Sieuwerts AM; Smid M; Meijer-van Gelder ME; Foekens JA; Hollestelle A; Martens JW Cancer Lett; 2016 Jun; 376(1):104-9. PubMed ID: 27018307 [TBL] [Abstract][Full Text] [Related]
35. Loss of function of GATA3 regulates FRA1 and c-FOS to activate EMT and promote mammary tumorigenesis and metastasis. Liu X; Bai F; Wang Y; Wang C; Chan HL; Zheng C; Fang J; Zhu WG; Pei XH Cell Death Dis; 2023 Jun; 14(6):370. PubMed ID: 37353480 [TBL] [Abstract][Full Text] [Related]
36. Combinatorial anti-proliferative effects of tamoxifen and naringenin: The role of four estrogen receptor subtypes. Xu Z; Huang B; Liu J; Wu X; Luo N; Wang X; Zheng X; Pan X Toxicology; 2018 Dec; 410():231-246. PubMed ID: 30153467 [TBL] [Abstract][Full Text] [Related]
37. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells. Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079 [TBL] [Abstract][Full Text] [Related]
38. Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells. Notas G; Kampa M; Pelekanou V; Troullinaki M; Jacquot Y; Leclercq G; Castanas E Mol Oncol; 2013 Jun; 7(3):595-610. PubMed ID: 23474223 [TBL] [Abstract][Full Text] [Related]
39. Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance. Bi M; Zhang Z; Jiang YZ; Xue P; Wang H; Lai Z; Fu X; De Angelis C; Gong Y; Gao Z; Ruan J; Jin VX; Marangoni E; Montaudon E; Glass CK; Li W; Huang TH; Shao ZM; Schiff R; Chen L; Liu Z Nat Cell Biol; 2020 Jun; 22(6):701-715. PubMed ID: 32424275 [TBL] [Abstract][Full Text] [Related]
40. Silmitasertib (CX-4945) Disrupts ERα/HSP90 Interaction and Drives Proteolysis through the Disruption of CK2β Function in Breast Cancer Cells. Kim H; Elkins E; Islam R; Cao B; Abbes N; Battles K; Kim S; Kim S; Williams C Cancers (Basel); 2024 Jul; 16(14):. PubMed ID: 39061141 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]